| DAY 1 Friday, September 2nd, 2022 |
||||
|---|---|---|---|---|
| Time (EET) in hrs | Theme | Moderator | Speaker | Talk title |
| 09:00 – 09:30 | REGISTRATION | |||
| 09:15 – 09:30 | OPENING OF THE CONFERENCE | Welcome by Toomas Asser, Rector, University of Tartu, Estonia | ||
| 09:30 – 11:30 | Personalized medicine in psychiatry | Lili Milani and Kelli Lehto | Professor Brenda Pennix Amsterdam UMC Netherlands |
Using genetics to unravel the heterogeneity of depression |
| Professor Henrik Larsson Karolinska Institute Sweden |
Psychiatric epidemiology using national register data: Challenges and opportunities | |||
| Dr. Christiane Gasse Ahrus University Denmark |
Title will be confirmed | |||
| Dr. Lu Yi Karolinska Institute Sweden |
A multidisciplinary approach to better understand treatment resistant depression | |||
| 11:30 – 12:30 | LUNCH BREAK | |||
| 12:30 – 14:00 | A tour at the Estonian National Museum | |||
| 14:00 – 16:00 | Immunology and Egigenetics | Pärt Peterson and Ana Rebane | Professor Dario Greco University of Tampere Finland |
Integrated approaches to chemical safety assessment and drug design |
| Dr. Ulf Andersson Vang Orom Aarhus University Denmark |
m6A RNA modifications, splicing and cancer | |||
| Dr. Benjamin Fairfax University of Oxford United Kingdom |
Exploring the interplay between germline genetic variation and responses to cancer immunotherapy and chronic viral infection across a large patient cohort | |||
| Anne Puel France |
Autoimmune phenocopies of inborn errors of immunity underlying infectious diseases | |||
| 16:00 – 16:30 | COFFEE BREAK | |||
| 16:30 – 18:30 | Genetic and phenotypic variance | Kaur Alasoo | Dr. Claudia Langenberg University of Cambridge/ Berlin Institute of Health at Charité United Kingdom/Germany |
From molecules to health records: utility of omics at population scale |
| Professor Karoline Kuchenbäcker London’s Global University United Kingdom |
Diversity in genomic studies: the transferability of complex trait loci and its impact on downstream applications | |||
| Elo Madisson Wellcome Sanger Institute United Kingdom |
A spatial multi-omics atlas of the human lung reveals a novel gland-associated immune niche | |||
| Ewan Birney EMBL-EBI United Kingdom |
Big data in biology: what the pandemic has taught us | |||
| 19:00 – 00:00 | DINNER at Estonian National Museum | |||
21st Gene Forum 2022
Tartu, Estonia
September 2-3, 2022 (Hybrid meeting)
| DAY 2 Saturday, September 3rd, 2022 |
||||
|---|---|---|---|---|
| Time (EET) in hrs | Theme | Moderator | Speaker | Talk title |
| 09:30 – 12:00 | Microbiome and population genomics | Mait Metspalu and Elin Org | Paul Wilmes University of Luxembourg Luxembourg |
Systems Ecology of Human-Microbiome Interactions in Health and Disease |
| Leo Lahti Univerity of Turku Finland |
Emerging computational approaches in population studies of the human microbiome | |||
| Adrian Tett University of Vienna Austria |
The impact of Westernization on the human gut microbiome | |||
| Hannes Schroeder University of Copenhagen Denmark |
Title will be confirmed | |||
| 12:00 – 13:30 | LUNCH BREAK | |||
| 13:30 – 15:00 | Parkinson Disease | Andres Metspalu | Professor Mart Saarma University of Helsinki Finland |
Search for new molecules to cure Parkinson’s disease |
| Dr. Alastayr Noyce London’s Global University United Kingdom |
Determinants of Parkinson’s disease – genes, environment and interactions | |||
| Dr. Toomas Toomsoo Confido Medical Center Estonia |
Association of the Polygenic Risk Score (PRS) With the Probability of Substantia Nigra Hyperechogenicity (SN+) in Non Parkinson’s Disease Adults” UUS ETTEPANEK: Polygenic risk score for Parkinson’s disease and probability of substantia nigra hyperechogenicity in “healthy” adults | |||
| 15:00 – 15:30 | COFFEE BREAK | |||
| 15:30 – 17:10 | – | – | Michael Simpson Kings College London United Kingdom |
Title will be confirmed |
| Lisa Bastarache Vanderbilt University Medical Center United States of America |
Studying rare variants at the population level: How EHR-linked biobanks give us new insight into monogenic disease | |||
| – | Presentation by Illumina | To be confirmed | Title to be confirmed | |
| 17:10 – 17:15 | CLOSING REMARKS | |||